Stephens Consulting’s Vaxcyte PCVX Stock Holding History

Stephens Consulting’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40	Closed	-$1.51K	–	1757
2025 Q1	$1.51K	Buy	+40	New	+$3.2K	﹤0.01%	507

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Stephens Consulting's PCVX Position: Q2 2025 in Review

Stephens Consulting sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 40 shares — an estimated $1.51K sold.

Stephens Consulting first reported a position in PCVX in Q1 2025 and held it in 1 quarter. The position peaked at $1.51K in Q1 2025. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Stephens Consulting reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 40 Vaxcyte shares in Q2 2025, an estimated $1.51K.
Stephens Consulting first reported a position in Vaxcyte in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Vaxcyte position peaked at $1.51K in Q1 2025.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.